Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 - Announced complete clinical response in first infant dosed by partner iECURE in ongoing Phase 1/2 clinical trial in Ornithine Transcarbamylase (OTC) Deficiency - Anticipated cash runway into the second half of 2026 is expected to enable achievement of key Phase 1 clinical inflection points across both wholly owned in vivo gene edi
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateBusiness Wire
- Prendio-BioProcure Launches New Generative AI, Analytics, and Workflow Automation Capabilities Enhancing its Market Leading Life Sciences P2P Technology Solution [Yahoo! Finance]Yahoo! Finance
- iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics MeetingBusiness Wire
DTIL
Earnings
- 3/26/25 - Miss
DTIL
Sec Filings
- 3/28/25 - Form 4
- 3/28/25 - Form 4
- 3/27/25 - Form 4
- DTIL's page on the SEC website